[go: up one dir, main page]

WO2008108344A1 - Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド - Google Patents

Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド Download PDF

Info

Publication number
WO2008108344A1
WO2008108344A1 PCT/JP2008/053791 JP2008053791W WO2008108344A1 WO 2008108344 A1 WO2008108344 A1 WO 2008108344A1 JP 2008053791 W JP2008053791 W JP 2008053791W WO 2008108344 A1 WO2008108344 A1 WO 2008108344A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
production
replication
plasmid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053791
Other languages
English (en)
French (fr)
Inventor
Atsuo Waki
Masayuki Aso
Junichi Fukuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellgentech Inc
Original Assignee
Cellgentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellgentech Inc filed Critical Cellgentech Inc
Priority to JP2009502578A priority Critical patent/JPWO2008108344A1/ja
Publication of WO2008108344A1 publication Critical patent/WO2008108344A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01026—Sterol O-acyltransferase (2.3.1.26)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　本発明の課題は、外来遺伝子としてのＬＣＡＴコードヌクレオチドを効率よく標的細胞で発現させることができる、患者に投与される遺伝子治療用細胞を産生するためのＬＣＡＴコードヌクレオチドを保持する複製欠損性レトロウイルスベクター、及び当該レトロウイルスベクターを産生するのに用いられるプラスミドを提供することにある。その解決手段としての本発明の複製欠損性レトロウイルスベクター産生用プラスミドは、レトロウイルス由来の５’側のＬＴＲ配列と３’側のＬＴＲ配列の間に、外来遺伝子としてＬＣＡＴコードヌクレオチド配列が挿入され、かつ、前記ＬＣＡＴコードヌクレオチド配列の５’側にコザックのコンセンサス配列及び前記レトロウイルスのパッケージングシグナル配列が連結されていることを特徴とする。
PCT/JP2008/053791 2007-03-02 2008-03-03 Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド Ceased WO2008108344A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009502578A JPWO2008108344A1 (ja) 2007-03-02 2008-03-03 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007052291 2007-03-02
JP2007-052291 2007-03-02

Publications (1)

Publication Number Publication Date
WO2008108344A1 true WO2008108344A1 (ja) 2008-09-12

Family

ID=39738222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053791 Ceased WO2008108344A1 (ja) 2007-03-02 2008-03-03 Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド

Country Status (2)

Country Link
JP (2) JPWO2008108344A1 (ja)
WO (1) WO2008108344A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090091A1 (ja) * 2010-01-21 2011-07-28 セルジェンテック株式会社 遺伝子治療用脂肪細胞の調製のための外来遺伝子の導入に適した細胞集団かどうかを判定する方法
US8071085B2 (en) 2002-06-18 2011-12-06 Eisai Co., Ltd. Primary cultured adipocytes for gene therapy
JP2012530070A (ja) * 2009-06-12 2012-11-29 アルファコア ファーマ リミテッド ライアビリティ カンパニー 貧血および赤血球機能不全を治療するためのｌｃａｔの使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511651A (ja) * 1995-05-10 1999-10-12 イントロヘーネ ベスローテン フェンノートシャップ 遺伝子治療に特に適した改良型レトロウイルスベクター
WO2003106663A1 (ja) * 2002-06-18 2003-12-24 エーザイ株式会社 遺伝子治療用初代培養脂肪細胞
JP2004516830A (ja) * 2000-12-05 2004-06-10 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 哺乳動物系における組換えタンパク質の均質性および分泌の改良

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
EP1892294A4 (en) * 2005-06-15 2010-04-14 Takara Bio Inc METHOD OF TRANSFERRING GENES IN FAT CELLS OR PRECURSOR FAT CELLS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511651A (ja) * 1995-05-10 1999-10-12 イントロヘーネ ベスローテン フェンノートシャップ 遺伝子治療に特に適した改良型レトロウイルスベクター
JP2004516830A (ja) * 2000-12-05 2004-06-10 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 哺乳動物系における組換えタンパク質の均質性および分泌の改良
WO2003106663A1 (ja) * 2002-06-18 2003-12-24 エーザイ株式会社 遺伝子治療用初代培養脂肪細胞

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071085B2 (en) 2002-06-18 2011-12-06 Eisai Co., Ltd. Primary cultured adipocytes for gene therapy
JP2012530070A (ja) * 2009-06-12 2012-11-29 アルファコア ファーマ リミテッド ライアビリティ カンパニー 貧血および赤血球機能不全を治療するためのｌｃａｔの使用
WO2011090091A1 (ja) * 2010-01-21 2011-07-28 セルジェンテック株式会社 遺伝子治療用脂肪細胞の調製のための外来遺伝子の導入に適した細胞集団かどうかを判定する方法
JP5806791B2 (ja) * 2010-01-21 2015-11-10 セルジェンテック株式会社 遺伝子治療用脂肪細胞の調製のための外来遺伝子の導入に適した細胞集団かどうかを判定する方法

Also Published As

Publication number Publication date
JPWO2008108344A1 (ja) 2010-06-17
JP2009201518A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
Brown et al. Nox proteins in signal transduction
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
SG10201908848RA (en) Pharmacologically induced transgene ablation system
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2001034206A3 (en) Nucleic acid-containing complex
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
WO2010127166A3 (en) Combination anti-hiv vectors, targeting vectors, and methods of use
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
WO2007118245A8 (en) Methods and compositions related to adenoassociated virus-phage particles
WO2010020935A3 (pt) Aplicação da monooleína como novo lípido adjuvante em lipofecção
WO2009065561A3 (en) System for delivery into a xcr1 positive cell and uses thereof
WO2010125471A3 (en) Gene vector
NZ582794A (en) Modified lecithin-cholesterol acyltransferase enzymes
WO2012008860A3 (en) Bacterial nitroreductase enzymes and methods relating thereto
EP4241854A3 (en) Lysosomal storage disease enzyme
WO2008108344A1 (ja) Ｌｃａｔ欠損症の遺伝子治療用細胞並びにこれを産生するのに用いられる複製欠損性レトロウイルスベクター及びプラスミド
WO2008153366A3 (en) Method for manufacturing active recombinant blood coagulation factor ix
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2009050657A3 (en) Genetically modified stem cells and methods for identifying tissues differentiated therefrom
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2008133157A1 (ja) 体温低下抑制剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009502578

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721211

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721211

Country of ref document: EP

Kind code of ref document: A1